The clinical application of two newly developed lipid emulsions (Solipid 20% S&E) in critically ill patients.
OBJECTIVE
The clinical compatibility of two newly developed lipid emulsions based on soy oil (20%) emulsified with egg lecithin (12 g/l) or soy lecithin (15 g/l) (Solipid 20% E&S) has been compared.


METHODS
Double-blind prospective randomized study.


METHODS
Intensive care unit of a university hospital.


METHODS
20 patients (16 men, 4 women, age 20-59 years) were entered into the study.


METHODS
One g of lipids/kg body weight per day was administered on day 1 and subsequently 2 g/kg/day on days 2-5. Blood was drawn once a day, lipids, lipoproteins, apoproteins and other routine clinical chemistry parameters were determined.


RESULTS
No significant increase of total triglycerides could be observed. Total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, apolipoproteins A I and B usually remained below the reference ranges. Electrolytes, uric acid and glucose, blood cells, parameters of liver and kidney function, coagulation and protein metabolism did not show relevant changes; only the activity of gamma-GT in both groups--independent of the sort of lecithin--increased significantly.


CONCLUSIONS
The results indicate adequate elimination of both tested lipid emulsions from the plasma at usual clinical conditions. Therefore Solipid 20% S&E can be used in critically ill patients.
Widhalm
K
K
Klinik für Kinderheilkunde, Universität Wien, Osterreich.
Kohl
S
S
Hammerle
A
A
D000328:Adult; D003422:Critical Care; D004311:Double-Blind Method; D005217:Fat Emulsions, Intravenous / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D008111:Liver Function Tests; D008297:Male; D008657:Metabolic Clearance Rate / Q000502:physiology; D008875:Middle Aged; D010289:Parenteral Nutrition, Total; D011446:Prospective Studies
D005217:Fat Emulsions, Intravenous; D008055:Lipids